Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
We'd like to start our call by going through a couple of highlights. First of all, we operate in a solid market, and the growth continues to be robust. We have made the decision to reduce our AOP program this year, which is in our MedTech business, where we are normalizing and phasing our revenues throughout the year. This is to match our customers' consumption with their deliveries and to streamline our supply chain and to be able to operate our business with lower working capital, both in inventory and accounts receivable. This change and this offer to our customers to move from annualized order programs where they would buy a full year's consumption at the beginning of the year, to switch over to a quarterly or a monthly order pattern has impacted our first quarter growth. In our MedTech segment. This has no impact on our full-year revenue, and the gap that was created in Q1 will be fully recovered throughout the remaining quarters of the year. We have strong momentum in both our Veterinary Services business and in our Specialty Pharma business. Both of these businesses are delivering robust double-digit growth. If we look at our customers in our MedTech segment that have never been participating in an AOP program, ever, that group of customers is also growing by double digits. In March, we announced new financial targets: our adjusted EBITDA above €300 million by 2030 and our net leverage of three or below. Those are good targets. And we also look forward to executing and delivering on those. We also did a rights issue with €1.6 billion, so that we have opportunities to go after and finance value-creating acquisitions. We also announced our intention to list on the main market. I'd like to thank our shareholders who participated and for your support in this process. We'll look at the next slide here and maybe talk about a few things more in detail. The first quarter organic growth came in at 1%. And driven by the reduction of the annual order program in our MedTech business. We had an additional contribution of 3% from acquisitions. We also did a small bolt-on acquisition in our tech segment. There's no impact of this for the rest of the year. So we have a phasing in MedTech, our EBITDA down to 26.3%. And this is a direct result of the reduction of our AOP program. Our Specialty Pharma, services, and diagnostics business delivered on the plan that we had for those businesses in the first quarter. And as you can see on this slide here, the light blue depicts the change in the AOP program. That was a €10 million program in the first quarter last year. That was reduced to a €5.5 million program in 2024. And moving over to our Specialty Pharma segment. We grew 11% there, and it was driven by our U.S. operations. Specialised Nutrition business and our European allergy test and treatment business. As we've mentioned before, we're focusing on driving organic growth through cross-selling products into new geographies and new channels. And we had a significant contribution of growth from those initiatives in the first quarter. Our margins have been stable over the years, and we had a solid 17% EBITDA growth going to our R&D and innovation track for Specialty Pharma. We launched 30 new products in the quarter, and our new allergy vaccine is progressing well where we have initiated studies on client dogs during the first quarter. And so far it's progressing very well. All in all, we see continued good positive momentum in our Specialty Pharma and foresee this business to continue to have very healthy growth going forward. Turning to our MedTech segment. The result of the decline in the AOP program is resulting in an organic decline of 12%, and it's solely described by the US and by the AOP program changes there. Again, we are matching customer demand with our deliveries, and it gives us an opportunity to reduce the volatility and increase the visibility, transparency, and predictability of this business. A lot of our customers that were offered a transition here, took advantage of it. So they are now on a monthly or a quarterly order plan. And that transition went a lot quicker and faster than we had anticipated. The AOP program is still available for customers who would like to order a full year volume at once and look at outside of the US, in Europe, in Asia-Pacific, and in Canada, where we do not have an AOP program, the customers there. And the revenues there have been delivering a high single digit growth for the first quarter. We have good underlying momentum in this business. And these facing changes in the first quarter will have no impact on the full year revenue. And going over to Veterinary Services. Organic growth here is 15%. And it's healthy growth across all of our geographies. It's predominantly driven by new member acquisition. We welcomed 350 new clinics during the first quarter. We have a good conversion of membership into a higher level tier. Our co-owned clinics are also progressing and developing very nicely. They're growing ahead of the market. Our margin development year over year was up 170 basis points and a solid growth of EBITDA of 28%. We see a stable and very positive trend in our Veterinary Services, and we foresee that this business will continue to deliver outstanding growth in the future. Ollie, who is joining us here today, will spend more time talking about some of the exciting growth opportunities that we have in this part of our business for the future. Going into our diagnostics business. Now we have a decline of 6% here, and this business is operating in an end market that has been a little bit tougher than all the other markets that we're operating in. The amount of disease outbreaks has been low during this period, impacting the need for testing. We're continuing our efforts to diversify our portfolio in the diagnostics segment, diversifying into the companion animal space. We are launching our AI-enabled parasitology platform for our companion animals here in the second quarter. And we are going to reinvest a larger portion of our earnings generated from the core of diagnostics into further diversifying and growing our footprint in the companion animal space. So we foresee that our margins in this business will be lower than they have been traditionally because of this reinvestment into diversification. We turn to our ESG efforts. Our strategy here is centered around our people, animals, and our planet, and we continue to focus on ESG, making good progress here. In February this year, we achieved a higher rating by MSCI. We got an A rating there, which we're very proud of. And it was driven by two distinct changes and improvements. We made one around people development and the other around our governance. We also released our sustainability report for 2023 here in April. And this slide, as we're showing here, is pretty busy. But I want to highlight a couple of things of importance here. More than half of our leaders are women. We trained 15,000 professionals in the animal healthcare space last year, and we launched 111 new products that improve the health of animals. We've also established a carbon reduction plan for scope one and two emissions. And for the first time, we reported on our scope three emissions as well. And during this period, we've also taken the opportunity to bring ESG criteria into our M&A and due diligence processes so that we have that as a basis also for evaluating new acquisitions. We're a young company, we're fast-growing, and we're very proud of the achievements we have made so far. But we recognize we're at the beginning of a journey here, and we will continue this important work and are strongly committed to driving really positive change for our people, our animals, and our planet. And with that, I'd like to thank you for your attention and hand it over to Corleone, who will walk through our financials in more detail. Over to you, Corleone.
Thank you, Patrick, and let us dive into the numbers and move to the next slide, giving you some further details on the first quarter. The adjusted EBITDA amounted to €24.1 million at a margin of 26.3%. The first quarter margin is, as Patrick said, negatively impacted by the reduced Annual Ordering Programme in MedTech. We report an operating profit of €13.4 million, down from €18.5 million last year, mainly as a result of the Annual Ordering Programme impact, as well as the higher non-recurring items of €5.1 million relating to acquisitions and the US litigation. The net financial items of -€7.9 million consist of three parts. The first element being financing costs of €6.5 million, with an average interest rate for the quarter of 6.7%. Secondly, contingent considerations where we have a net negative impact of €5.8 million. The quarterly discounting impact amounts to 1.8 million, and a negative impact from probability adjustments amounts to 3.0 million. Reflecting the strong performance in global pet products and services. And finally, a positive impact of 3.4 million from exchange rates. The income tax expense for the quarter amounted to €1.8 million. And all of the above resulted in a net profit for the quarter of €3.7 million. Turning to the first quarter cash flow, where cash flow from operating activities reached 11.2 million in the first quarter. And it's positive that we continue to see an improvement in cash generation in our businesses. Net working capital amounted to 75.3 million at the end of the quarter. Equal to 22% of revenue, which is an improvement in relation to sales from the same period last year. Compared to the end of December 2023, inventory declined by 0.6 million, driven by continued inventory reduction in MedTech. Accounts receivable increased by 11 million, as AOP revenue is paid in installments during the year, and US specialized nutrition build up trade receivables after strong growth in March. Accounts payable increased by 6.8 million in the quarter. Cash flow from investing activities was 6.1 million, primarily reflecting capital expenditure of 3.9 million and acquisitions of 2.6 million, which include the acquisition of Veterinary Transplant Services, VTS in MedTech. The capital expenditure is split between 2.5 million investments in intangible assets and 1.4 million investments in property, plant, and equipment. The main areas for investments are capitalization of R&D and expansion of laboratory capacity in Specialty Pharma, investments in manufacturing capabilities in MedTech, and development costs related to the VetFamily platform. Investment in Veterinary Services. Cash flow from financing activities of 4.1 million includes 3 million repayment of debt. Moving to the next slide. Looking at net debt and leverage for the quarter where net debt amounted to 287.4 million with leverage of 3.0 times, which is a similar level as the previous quarter. Cash and cash equivalents amounted to 38.1 million at the end of the quarter. External lending of 301 million, broadly in line with 302 million at the end of December, as repayment of 3 million was offset by unfavorable currency movements. With the funds from the capital raise of slightly above €140 million received in April. The leverage has come down to 1.5 times during the first quarter. We also signed an amendment to our bank agreement, adding another 70 million to our existing facilities. The capital raised, together with the amended bank agreement, has put us in a good position to pursue strategic value-adding acquisitions. Now, handing over the word to Olli for a deep dive into Veterinary Services. Thank you, Cologne, and good morning, everyone.
I'm here today to give you a short overview of the Veterinary Services segment within the Vimian Group. VetFamily, as we call it, is a global leading veterinary service platform currently supporting over 7550 members across 11 markets. Historically, predominantly being a Nordic procurement organization, we have during the last years transformed the business with a wider set of key services as well as offering a vibrant community for our members across four continents. We also partner with most of the leading animal health companies of the world, allowing them to efficiently access and engage with our members. Being an independent clinic is challenging and overwhelming, especially with all the non-care tasks you need to address today that spend around 50% of their time on non-care related work. Through the services of VetFamily, we help our members overcome these non-care tasks and allow them to focus on the core of their business, the pets. Our mission is to empower the independent veterinarians of the world to stay competitive and relevant in a fast-moving and changing environment. Therefore, we continuously invest and develop our platform to enhance our support for our members. Our revenue streams can, on a high level, be divided into three main areas, all benefiting from each other. Within partner services, we have commercial agreements on a local, regional, and or global level with key industry partners, giving our members the benefit of scale and our partners an efficient way to access and engage with our vibrant member community. Approximately 40 to 50% of our revenue comes from partner services. Within clinic services, we offer value-added services our members use to evolve their clinics and develop their ways of working. The longer we've operated in the market and the more mature the market is, the more value-added services we tend to offer. 20 to 25% of our revenues come from clinic services. Within the corporation. We currently run a co-ownership program with 11 clinics. We see these clinics and entrepreneurs as innovation hubs. That gives us the opportunity to develop and test new ideas within important focus areas, benefiting our entire membership ecosystem. Our clinic operations stand for 30 to 40% of our revenues. Looking at our development and achievements since the IPO, we have more than tripled our revenues with a revenue CAGR of 51%, we have increased our membership base from 2600 to over 7550 member clinics. We have gone from seven European countries to 11 countries across four continents through acquisitions in Australia and the US, as well as organic entries into Brazil and Belgium. Our global reach has increased our relevance with our partners, and with a larger number of clinics now supporting, we've changed our one size fits all approach to our tiered and tailored offering, better meeting the needs of both clinics and partners. We have done focused investments into capabilities within digital data and insights, evolving our service offering and relevance, and we have invested into our organization, bringing in additional key talent and prepared our team for accelerated growth beyond our current achievements. We are the only company doing what we do at a global scale, and I'm very proud of the development we've had as an organization since the IPO. But we're far from done. There are several avenues of growth we're pursuing, and the need for our services increases every day that passes. We can continue growing by adding new members, member clinics within the 11 markets we're currently operating. We can expand our service offering to existing members and partners. We can expand organically into new geographies, which we have a proven track record of, and we can leverage our M&A ability to support and accelerate all avenues of growth, as well as utilize the means, geographical and industry footprint. The growth we've enjoyed so far shows the value our services bring to the independent vet community, and I truly believe we can. We will continue to play an important role for our partners and member clinics around the world.
Thank you. Thank you very much.
Much, Ali. Clearly, there are a lot of exciting growth opportunities in our veterinary services business. Um, so we're coming to the end of our prepared presentation here. So in the first quarter, we've taken some strategic decisions to continue to build a strong platform for continuous value delivery for many years to come. The new financial targets are a part of that. The successful rights issue and the important decision now to phase out the revenue throughout our MedTech business that has a short-term impact on Q1, but no impact on the full year. I'm excited to be on board. And Vivien and I lead the company for a long-term journey to allow continued growth and value creation in the animal health space. The market is solid that we operate in. We are.
Great.
In terms of how we are positioned in that market to take advantage of the market growth and grow above and beyond what the market is doing. We saw some strong performance in our Specialty Pharma and Veterinary Services business, as we've seen here earlier today, with the double-digit growth and maintained or improved profitability. And we're building a strong foundation for the future. And with that said, I'd like to thank you for your attention and open up for Q&A. Thank you very much.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from a delegation from Jefferies. Please go ahead.
Good morning. My first question is on the MedTech division here. Um, I think you said that if you were to exclude the reduction in AOP, which is limited to the US market, then growth would have been high single digits. Um, within the segment that's true.
And. Yeah. Good morning. Adele. Yeah. So what we're saying is that the actual growth outside of the US is high single digits.
Okay. Got it. Um, but then I think at the end of Q4, when you presented, you said that January was high single digits for the group. So I'm just trying to reconcile how, I guess was the growth. The growth gets slower throughout the latter half of the quarter. Or is there anything in the other segments that contributed to the low organic growth in Q1 outside of MedTech?
No.
Sorry. Morning. No. As Patrick said, we had a good performance in the other segments in the quarter, seeing double-digit growth in both Veterinary Services and in Specialty Pharma. Uh, as I said, in diagnostics, there's still some headwinds in the sector that we see. And we saw a small decline in diagnostics in the quarter for MedTech. As you alluded to, and Patrick as well, we saw double-digit growth outside the US in the quarter and also in the Annual Ordering Programme, we wanted to make a shift to better match sales and deliveries with the underlying consumption. This was more successful than we anticipated and that we foresaw during the quarter. And that's a big shift for MedTech in the quarter. And the significant change or deviation from what we initially expected in the quarter. But as Patrick said, we don't see that that will have any impact on the full year numbers. It's just the phasing of sales in the US.
Got it. And is that expectation based on visibility that you have with your customers, underlying demand, or how can you be so confident that growth for the full year won't have an impact?
Yeah, that's a great question. So we're tracking the customers who took up the AOP program in 2023 but did not participate in the AOP program in 2024, and they've now shifted over to either monthly or quarterly orders. And we're tracking all of those customers. And when we see their order pattern, we're very confident that they will make up that difference throughout the remainder of this year.
Okay. Got it. Then I'm assuming that the reception so far from your customers has been positive. There's been no one pushing back on this. The strategic decision here.
No, it's voluntary. You know, we're offering them the chance to change from an annual program into either a quarterly or a monthly. And we've been overwhelmed by how many have actually taken up on that offer and switched. So it's well received.
Okay. Um, and then on diagnostics, uh, the question, the comment here about, um, margins being lower, uh, because of your decision to reinvest into the companion animal diagnostics, uh, is the margin going to be lower because of the initial cost base being elevated, or is the companion animal diagnostics segment a lower margin business versus, um, livestock diagnostics?
And the way we look at it, Adele, is that we're investing to put a more diverse portfolio in diagnostics. We're a little bit too dependent on the livestock market there. So it's going to be an investment in terms of a cost increase, in the short term, to build up a capability predominantly on the commercial side, to sell these products into the companion animal space.
Okay. Got it. And then maybe a question for Ali, if I may. Uh, if he's still on the line. Yeah. Great presentation here on Veterinary Services. I don't think you have any exposure to the UK within this segment, but it would be great to get your view on the CMA's current review of the veterinary industry there. And if this presents an opportunity or a challenge for you, should you want to expand into the UK, or no impact at all.
Um, thank you for the question. We have no UK exposure at all in our operations. But in general, we support the investigation and look forward to seeing what the outcome of that is. But I think the services we offer and the way we support the independent vet community will benefit from that.
Got it. Um, and then lastly, M&A, which is the question everyone wants answers to. What does the pipeline look like now, with their rights issue being completed?
Yes. Since we last discussed this, our pipeline has continued to grow. And, the deals that we talked about a few weeks ago, they're progressing forward. So we feel very good about the M&A pipeline and our opportunity to buy value-creating companies in there and add to our existing business.
So it's still a combination of both organic and M&A growth that you're looking at.
Yes, that's correct.
Great. Thank you.
The next question comes from Vineet Agarwal from Citi. Please go ahead.
Oh. Hi there. Um, we need some clarity. I just want clarification on the M&A contribution, I think. On slide three, you mentioned the contribution of 3% in MedTech. But if I look at the financial report, I can see that the acquisitions didn't contribute anything in MedTech but actually in Specialty Pharma. So I'm just wondering if you can clarify that and then, just on Veterinary Services margin, can you give any flavor as to what the margins would have been, excluding those investments in the digital services platforms? And are these investments largely done, or are they likely to put some more pressure on the margins throughout 2024? And then finally, I know that historically you have given some sort of trading update into the quarter. I know you don't give any guidance, uh, but you did use to provide some sort of color into the quarter. Um, just wondering if you have stopped that or, can you give us some flavor as to what April looked like? And, um, yeah, I mean, May is only two days away, so maybe. How did they shape up?
Good morning, and thank you for your question. Let me answer questions one and three. And then I'm going to ask you to clarify question two. Sorry, but taking question one, and just to sort that out. And so you understood it correctly, in Specialty Pharma and in Veterinary Services, we have a contribution from acquisitions of, let's say, 6 to 7%, within those two segments. Within that context, there's no contribution from acquisitions in the first quarter in our numbers. Then, to your third question, in terms of, sort of. Current trading and full-year expectations. As we said, if we adjust for the MedTech sort of change in the quarter and removing a large part of the seasonality of MedTech, that also contributed to the seasonality of the group. We see stable development in the first quarter. We have started the second quarter according to expectations. And, uh, so we feel confident and are positive about our expectations for the full year. So, we haven't changed our perception or perspective regarding the full year from that then, and also, I said we're making a strategic change, with a target to move to the main market within Q1 next year. And as a consequence, as you noted in the last couple of quarters, we are tightening our reporting processes continuously and reporting in a more timely fashion to the market. And as a consequence, also, the current trading update in the quarter becomes less and less relevant. So sorry. Could you just repeat the second question for me, and I'll try to give you a good answer on that one as well.
No, I was just checking on the web services. Margins. Can you give any sort of flavor as to what the margins would have been, excluding those investments in the digital platform? And are these largely done, or likely to put some more pressure on the margins throughout 2024?
I can start and then maybe I can give some more color. If you look at Veterinary Services, in the last couple of quarters, we've seen a nice, continuous margin improvement in Veterinary Services in the last couple of quarters. Good solid revenue growth. Good strong organic growth. And you see the continuously positive margin development in the first quarter of this year. It's better than the first quarter of last year. There is some, you could say, small seasonality between the quarters. And secondly, as we mentioned, we have taken conscious decisions to invest in the digital platform. To ensure continued good growth and margin development within Veterinary Services going forward. I can let maybe give you some additional color too, so the investments and development for Veterinary Services.
Yeah. No, I mean, I can just only reiterate we've.
We've.
Improved our margin by 170 basis points since the last quarter. A big part of our success is balancing the investments we do into the platform to support the community and allowing them to grow. If we hadn't taken those investments we mentioned this quarter, of course, the margin would have been higher. And, I don't feel any, I feel comfortable with our margin not being additionally pressured during the year.
Thank you.
The next question comes from Rickard and Kranz from Handelsbanken. Please go ahead.
All right. Good morning, and thank you for taking my questions. Just trying to get a sense a little bit, on the moving parts and expectations for the full year, a little bit on growth and margins. So, you know, is it still reasonable to achieve a sort of high single-digit growth profile for the group, in the year given the slower start and, as I understand, in the Annual Ordering Programme, there was some discounts given to the customers for ordering in bulk. Is that discount still, in the monthly or quarterly contracts? So, you know, we should expect a little bit of margin pressure in the MedTech segment in the coming quarters from that, or maybe help us understand a little bit of the moving parts. So I'll start there. Thank you.
Yeah.
Good morning, Richard, thank you for your question. Um, the Annual Ordering Programme refinancing that's going on now, where customers will switch from buying on the full year to buying in monthly or quarterly, uh, will have no impact on the full year. So you'll see a full recovery. And if we look at how those customers are behaving, now that they've switched to that type of order pattern, they're behaving exactly as you would expect them to behave for them to order the same amount of volume, but through a different timing throughout the year. So you will see Q2 and Q3 and Q4 recover the revenue gap that was created here in Q1. So from a full year perspective, this doesn't change how we think about the full year at all. Uh, neither on the top line nor on the margin side.
That's very clear. Um, and, uh, also thank you for the presentation there as well. I was wondering if you could perhaps add some more insights and commentary on the rationale, uh, behind the clinic operations and direct investments into vet clinics, you know, clearly a lower margin and less scalable business than the remaining part of the operations. So maybe add some more, uh, details on how you're thinking going forward. Do you intend to expand that part of the business, and how should we think about it as synergistically with, with the remainder of the VetFamily group. Thank you.
Thank you for the question. Um, I mean, we have the co-ownership program to offer entrepreneurial veterinarians. I want to continue developing their clinics and at the same time contribute positively to our entire community. These are clinics that want to be in the forefront of how we should run and operate a modern clinic for the future. Uh, so we see these clinics and entrepreneurs as innovation hubs. That gives us an opportunity to develop and test new ideas within important focus areas. So although these clinics stand alone, have a different growth and profitability profile than other parts of the business. We look at our business as a whole and how each part can contribute to the total business over time. And we see synergistic opportunities in between. In terms of future acquisitions. It's kind of hard to comment on that specifically, but we always evaluate value-creating opportunities. And that's also the case when it comes to the co-ownership program.
All right. Thank you. And just to squeeze a final quick one in. Any update or insight into heading into April or sort of end of the quarter from the avian influenza update we're seeing and some of the headlines we're seeing in media. Just wanted to check if there's anything to flag there.
Yeah, I know, and that's very well spotted on market activities. Now, of course, we're aware of that outbreak. It's sort of so far it hasn't moved that much into production. Animal health, I would say, has still been predominantly focused on wildlife. We're starting to see a little bit of spread into cattle, especially in the US where we are working closely with our partners to see how we can support the labs and our customers with this outbreak. But we haven't seen any, I would say, any large effects from a commercial point of view so far.
That's very clear. Thanks for taking my questions.
Thank you.
The next question comes from Kavya from UBS. Please go ahead.
Hello. Thank you for taking my questions. Um, I just had a couple of questions on the Annual Ordering Programme. Um, so just on the first one. So it's now currently €5.5 million, right? Is this a level that you would expect it to remain at? Or would you look to further reduce it going forward and invite more customers next Q1 to switch to monthly or quarterly ordering patterns? And my second question was just in terms of your other two competitors, in terms of the veterinary orthopedic implant market? Um, is the Annual Ordering Programme, is this sort of standard practice or was this programme kind of unique to Maverick? And then the third one, if I may, is just, I was just curious to understand. Presumably, there was a discount attached to the Annual Ordering Programme (AOP). Um, and so does this now go away when you switch to monthly and quarterly ordering? I'm just. I guess I'm just trying to ask sort of what was the incentive for people to switch over. Was there an economic incentive in any way? Thank you.
Yeah.
Now, thank you very much for your questions. So it's a 4.5 million program reduction this year. Euros. And I think your question was, you know, how is this going to play out. And in Q1 2025. And if we look at the amount of customers that switch this year, there might be a few that will decide to switch again next year. It's hard for us to predict if there is any switching going on next year, it would be significantly smaller than what we've seen this year. It might be a significantly reduced impact, but again, the program is now relatively small compared to our total revenue anyway. So that's the first way of looking at what might happen in Q1 2025. And then your second question was around the Annual Ordering Programme. Is it common in the industry or not? The program was born at a time when several companies in the space, particularly in the US, had some supply chain issues and delivery issues, and it was almost an insurance program for customers to always have availability of products when several people had trouble delivering products. We don't have any delivery problems anymore. I think that's true for us and all of our competitors too. So that way you can kind of now adjust the program. There are no particular going back to the discounts, or there are no particular incentives to move from the annual order program into the monthly or the quarterly program. So there will be no impact on discounts or anything like that. So, people are moving because they think it's a better way to order to match their consumption with the deliveries they're getting from us.
Thank you very much. That's really clear. And, so just to clarify, prior to this year, was it compulsory for all US customers to be on the annual ordering program? If we just look at last quarter, were there still customers that could have the choice to order in a month?
You've always had a choice. But we had a very large uptake last year, an extraordinarily large uptake last year. And, we don't really see why the annual order program is so beneficial. You know, we think it's better to match the consumption with the deliveries, but the annual order program still exists. So customers who want that? We'll sign them up for AOP and customers who do not want it. We sign them up for another order pattern. So we'll adjust to what our customers would like and how they would best like to do business with us.
Thank you. That's very helpful. Thank you very much.
Thank you.
The next question comes from Arvid McCann from Carnegie. Please go ahead.
Good morning, and thank you for taking my question. So first off, regarding Specialty Pharma, can you say anything about the rollout of the Ovacyte test in the US? Is it starting to pick up any speed? And secondly, what are you observing? The need to invest, to increase investment in diagnostics. Does that come on the back of lower than hoped for uptake of new potential growth drivers for 2024? I guess, primarily oversight, or is that still too early to tell?
Yes.
So we're seeing an improvement in the rates in our US allergy business, but I think we still have a way to go there until that's in the shape and in the growth rates that we would anticipate and likely to see. And we're using our European business as kind of one of the proxies there where we're very successful with this particular product. And in that segment, we're working to get to the same level in the US, but we have a way to go to get there. Your question about diagnostics is correct. We're launching the Oversight product right now. And the prior question here is that we're investing in the go-to-market structure for that, to ramp up sales in that segment. And I think the way we think about this is that we will expand some costs in opex, as part of building this up. And that will deteriorate the margins in the diagnostics business until we see the revenue ramp, come up and match, which I think there's a delay between the two of them.
Is it possible to quantify the opex spend, compared to last year's or the increase for 2024? When it comes to diagnostics.
We think so. Looking at diagnostics and taking the two of them, we see and as you saw, I would say, still in the quarter, even with some investments in companion diagnostics, initiated this quarter. And we see more of the full effect in the coming quarters from that investment in terms of cost base. And that, as Patrick said, revenue will ramp up. Looking at, oh, sorry, livestock diagnostics, we still have a very healthy margin in that business. And we see that continuing the investments that we're doing now in companion animals. And it's, of course, difficult to speculate on how quickly the revenue ramp will be. And I think we'll have to come back to that in coming quarters. But we're expecting the investments in companion, having the total margin for diagnostics, to be more in single digits for the next 1 to 2 quarters.
Okay.
Fair enough. Thank you.
And lastly, how should we think about M&A-related costs for 2024? So, I understand that it's of course hard to estimate integration costs for potential acquisitions. But it seems like there's some fairly recurring costs baked into the M&A related noise, such as sourcing, stay-on bonuses, etc. So, as you increase the focus on M&A, should we expect the base to
Increase.
Significantly from the coming quarter even if no acquisition is made?
Uh.
So, a very relevant question. As you say, there are a few, and if you're looking at the quarter there, there are costs related to, you could say, earnout related costs. Those will start to move away here within a few quarters. Then, as you rightly point out, it's difficult to have a sort of good insight into exactly what cost will be in relation to M&A going forward. Because, as you say, it depends on what type of acquisitions we will engage in, the timing of those, and the sizes of those acquisitions. I would say it's fair to assume that there will be some costs in the coming quarter in relation to us pursuing and hopefully executing on M&A opportunities.
All right. Thank you so much. That was it for me.
The next question comes from Patrick Lin from DNB Markets. Please go ahead.
Hi, guys.
Thank you for taking my question. I have a follow-up on this Annual Ordering Programme, if I may. I mean, you show on one of the slides that the AOP has declined from 10 million to 5.5 million this year. But when we look at your total sales, I can exclude the AOP. I mean, you end up with having flat development from €26.5 million to, yeah, €26.5 million this year as well. But at the same time, you're saying that the clients that are not participating in the AOP program are growing double-digit, and it's the high single-digit growth in Europe and the APAC and Canada. So somewhere down the line, there seems to be some part of the business that is not doing as well as expected. So maybe you can elaborate a little bit on where we should see the shortfall in growth this quarter.
Thank you very much, Patrick. That's an excellent question. So there is a group of customers that we've encouraged to go into AOP and we really boosted them up. They're not part of the 10 million in this calculation because the 10 million is our normal AOP customer base. We boosted up another 3 million with additional customers that we kind of enticed them to go into AOP last year, and they were newly acquired customers from our acquisitions and other things like that. So we expanded the Annual Ordering Programme (AOP) last year, and they're not part of the calculation, which is also the gap that you're kind of looking for is that classification of those customers. So there's a €3 million kind of delta that you can put in either category, and they're not normal AOP customers. So we didn't want to reflect them there. But we did encourage all of them to do annual ordering programmes last year. They have also not replicated that this year.
Okay. So, what you're saying is really that the 10 million that you show on page three is. I mean, in reality, it was 13 million last year, but the 3 million was, you know, customers that you more or less pushed into the AOP programme.
Yeah, I think they.
Were interpreting.
It right.
They were first-time AOP customers and the way that it's played out here, there was the first time and the only time.
Okay, great. And then the second question, I mean, if a client that has been an AOP client in the past this year decides to do, say, monthly or quarterly ordering instead, do they have the choice to go back to an annual programme next year?
Absolutely. Any time. Okay.
Yeah.
Okay, great. Uh, good. That's all for me. Thank you.
Thank you.
As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Thank you very much. Thank you for your interest in our first quarter report. Thank you for your questions. We really appreciate it. We look forward to continuing to create a great animal health company and create value for our shareholders, our veterinary customers, and our employees going forward. Um, I look forward to seeing you again in the second quarter. Take care and have a wonderful day.



















